Atreca, Inc.
NASDAQ: BCEL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John A. Orwin
- Employees
- 90
- Headquarters
- South San Francisco, United States
- IPO year
- 2019
- Market cap
- $3.6M
- Website
- https://www.atreca.com
Loading BCEL…
Loading profile data…Frequently asked questions about BCEL
What does Atreca, Inc. (BCEL) do?
Atreca, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing antibody-based immunotherapies for various solid tumor indications. Its lead investigational therapeutic, ATRC-101, is a monoclonal antibody distinguished by its novel mechanism of action and a unique target, both identified through the company's propr...
Where does BCEL trade?
Atreca, Inc. (BCEL) trades on the NASDAQ Global Select.
What sector is BCEL in?
Atreca, Inc. (BCEL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Atreca, Inc.?
John A. Orwin is the chief executive officer of Atreca, Inc. (BCEL).
Where is Atreca, Inc. headquartered?
Atreca, Inc. is headquartered in United States.
Does BCEL pay a dividend?
Atreca, Inc. (BCEL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BCEL go public?
Atreca, Inc. (BCEL) completed its initial public offering in 2019.